Zosano to Present Migraine Data at Three Industry-Leading Conferences
01 6월 2017 - 9:30PM
Late-Breaking Oral and Oral Presentations to
feature M207 Acute Migraine Therapy
Zosano Pharma Corporation (NASDAQ:ZSAN), a specialty pharmaceutical
company that recently established a differentiated safety and
efficacy profile in a pivotal trial with its lead product, M207, as
an acute treatment for migraine, today announced that three
conferences have accepted Zosano submissions for oral presentation
at their annual meetings. Zosano will have a late-breaking
oral presentation at the American Headache Society meeting in June,
as well as an oral presentation at the International Headache
Society meeting in September. In addition, Zosano has been
selected to present at the Transdermal and Intradermal Drug
Delivery Systems conference, also in September.
“The selection of our data for oral presentations at these key
medical meetings underscores the need for new therapies for
migraine patients,” said Don Kellerman, Vice President of Clinical
Development and Medical Affairs at Zosano. “We believe that it is
important to increase awareness of M207 and its compelling clinical
results among key opinion leaders as well as community physicians.”
“The clearly differentiating data from our Zotrip trial
highlights the potential of our lead migraine product as well as
the underlying technology that has made its clinical results
possible,” said John Walker, Zosano’s Interim CEO and Chairman of
the Board of Directors. “These presentations offer a forum to
present M207 as a primary treatment option, if approved, for acute
migraine sufferers who seek a therapeutic option that is both fast
acting at onset and offers a durable response.”
Below is a schedule for the oral presentations:
Conference: |
American
Headache Society (AHS) 59th Annual Scientific Meeting |
Presentation
Title: |
“Effectiveness and
Safety of a New Zolmitriptan Rapid Absorption Microneedle Array
(M207) for the Acute Treatment of Migraine (The Zotrip Study)” |
Date: |
Saturday, June
10, 10:00 AM |
Location: |
Boston, MA, Westin
Boston Waterfront |
Abstract: |
IOR13LB |
Conference: |
18th Congress
of the International Headache Society |
Title: |
“Comparative Effects of
3 Doses of Zolmitriptan Patch (M207) and Placebo on Pain and Most
Bothersome Symptom for the Acute Treatment of Migraine: The
Zotrip Study” |
Date: |
September 9, 2017, 11
AM |
Location: |
Vancouver, Canada,
Vancouver Convention Center |
Abstract: |
IHC2017-157 |
Conference: |
Transdermal and
Intradermal Drug Delivery Systems 2017 |
Title: |
Clinical Trial
Experience with the Intracutaneous Microneedle Systems: Experience
in Osteoporosis, Diabetes, and Migraine |
Sponsor: |
PharmaEd Resources
Inc. |
Date: |
September 28, at
1:15pm |
Location: |
Philadelphia, PA,
Racquet Club of Philadelphia |
About Migraine
Migraine is the leading cause of disability among neurological
disorders in the United States according to the American Migraine
Foundation. Migraine symptoms can include moderate to severe
headache pain combined with nausea and vomiting, or abnormal
sensitivity to light and sound. According to the Migraine
Research Foundation, migraine affects 30 million men, women
and children in the United States. Most migraines last between four
and 24 hours, but some last as long as three days. According to
published studies, 63% of migraine patients experience between one
and four migraines per month. According to Decision Resources,
prescription drug sales for migraine in the top seven countries
were estimated to be $3.3 billion in 2015, and are expected to grow
to $4.4 billion in 2020. Triptans, a family of tryptamine-based
drugs first sold in the 1990s, account for almost 75% of
anti-migraine therapies prescribed at office visits.
About M207
M207 is our proprietary formulation of zolmitriptan coated onto
our patented intracutaneous microneedle patch, which is then
applied with our proprietary applicator to ensure uniform and
consistent application. In February 2017, the Company announced
statistically significant results from the ZOTRIP trial, which
demonstrated that the 3.8mg dose of M207 met both co-primary
endpoints, achieving pain freedom and most bothersome symptom
freedom at 2 hours. In a Phase 1 trial, M207 demonstrated
markedly faster absorption kinetics compared to oral zolmitriptan.
The Company presented these results at the 2016 annual meeting of
the American Headache Society.
About Zosano Pharma
Zosano Pharma Corporation is an emerging CNS company focusing on
providing rapid symptom relief to patients using known therapeutics
and altering their delivery profile using the Company's proprietary
intracutaneous delivery system. The Company's goal is to make
intracutaneous drug delivery a standard of care for delivering
drugs requiring fast onset of action. Zosano Pharma has developed
its proprietary intracutaneous delivery system to administer
proprietary formulations of existing drugs through the skin for the
treatment of a variety of indications. The Company believes
that its intracutaneous delivery system offers rapid and consistent
drug delivery combined with ease of use. The Company is focused on
developing products that deliver established molecules with known
safety and efficacy profiles for markets where patients remain
underserved by existing therapies. Zosano Pharma anticipates that
many of its current and future development programs may enable the
Company to utilize a regulatory pathway that would streamline
clinical development and accelerate the path towards
commercialization. Learn more at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the timing of expected clinical development milestones, sufficiency
of our capital resources and need for future funding and other
future events and expectations. Readers are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict
and actual outcomes may differ materially. These include risks and
uncertainties, without limitation, associated with the process of
discovering, developing and commercializing products that are safe
and effective for use as human therapeutics, risks inherent in the
effort to build a business around such products and other risks and
uncertainties described under the heading "Risk Factors" in the
Company's most recent annual report on Form 10-K. Although we
believe that the expectations reflected in these forward-looking
statements are reasonable, we cannot in any way guarantee that the
future results, level of activity, performance or events and
circumstances reflected in forward-looking statements will be
achieved or occur. All forward-looking statements are based on
information currently available to Zosano and Zosano assumes no
obligation to update any such forward-looking statements.
Zosano Contact:
Georgia Erbez
Chief Business Officer and
Interim Chief Financial Officer
510-745-1200
Investor Contact:
Jamien Jones
Blueprint Life Science Group
415-375-3340 x 5
jjones@bplifescience.com
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024